Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Cigarette Smoking, Smoking Cessation
Interventions: Impacto 2.0, quitSTART; Behavioral
Lead sponsor: Michael J. Zvolensky, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medulloblastoma
Interventions: Bridging Chemotherapy, Induction Cycles A1-A3, Induction Cycles A4-5, Consolidation Cycle A6, HIT-SKK Chemotherapy Cycles B1-3, Modified HIT-SKK Cycle B4-5; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2038
U.S. locations: 2
States / cities: Birmingham, Alabama • Columbus, Ohio

Conditions: Healthy Adult Participants
Interventions: 0 mg oral nicotine pouches, 3 mg oral nicotine pouches, 6 mg oral nicotine pouches, cigarette or e-cigarette; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: T-Cell Lymphoproliferative Disorder
Interventions: IdentiClone Dx TRG Assay; Diagnostic Test
Lead sponsor: Invivoscribe, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Physical Activity, Cognition, Habits
Interventions: Non-PA Action Planning, PA Action Planning, Consistency in Action Plans; Behavioral
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 60 Years and older
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Metastatic Breast Cancer
Interventions: ConvitVax; Biological
Lead sponsor: Jacinto Convit World Organization Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
Interventions: SOLTIVE Premium SuperPulsed Laser System; Device
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Knee Osteoarthritis
Interventions: Health Aid, Decision Aid; Other
Lead sponsor: David Ring; Other
Eligibility: 18 Years to 89 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hemophilia A or B
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
Interventions: BFB-101 (AAV9-CBh-AP4B1); Biological
Lead sponsor: BlackfinBio Ltd; Industry
Eligibility: 12 Months to 60 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative
Interventions: AirSeal® Insufflation System (AIS), Lexicon AP 50/30 Insufflator; Device
Lead sponsor: SurgiQuest, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Post Traumatic Stress Disorder
Interventions: Transcranial Direct Current Stimulator, Written Exposure Therapy; Device · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: β-hydroxy-β-methylbutyrate (HMB); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Autism Spectrum Disorder (ASD)
Interventions: ¡Iniciando! mHealth App; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stage 1 Diabetes Mellitus, Type 1
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obtaining OCT (Optical Coherence Tomography) Images
Interventions: Self-administered OCT imaging system, Technician-acquired OCT imaging; Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions: smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources; Other
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Cord Injury
Interventions: Paired Associative Stimulation, Locomotor Training, Sham stimulation; Device · Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Back Pain
Interventions: Battlefield auricular acupressure, Sham; Procedure
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Interventions: Sacituzumab Tirumotecan; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Overall Survival (All-cause Mortality)
Interventions: Control, Exercise; Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 55 Years to 74 Years
Enrollment: 19,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Transfusion Reaction, Hemolytic
Interventions: 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs; Device
Lead sponsor: Cerus Corporation; Industry
Eligibility: 4 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Impacto 2.0: Mobile Smoking Cessation Across Texas

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

Understanding Oral Nicotine Pouch Use in Healthy Volunteers

Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

Planning Actions for Consistent Engagement

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

Modified SOLTIVE Study

Health Aid for Knee Osteoarthritis

A Study to Describe Patient REal-world FitusiRan ExpeRience

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

Gastrectomy at Low Pressure Trial - (GALPT)

Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI

Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families

GLP-1 RA for Stage 1 Type 1 Diabetes

Self-Monitoring OCT

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

Improving Walking After Spinal Cord Injury

Battlefield Acupressure for Acute Back Pain Management in the Emergency Department

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

Terazosin And Metabolic Engagement in Alzheimer's Disease

Exercise and Mortality in Middle-Aged and Older Adults

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs